Reducing effect of the positive allosteric modulators of the GABA(B) receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats
Bernard B. Brodie Department of Neuroscience, University of Cagliari, Viale Diaz 182, I-09126 Cagliari (CA), Italy. European Journal of Pharmacology
(Impact Factor: 2.53).
12/2005; 525(1-3):105-11. DOI: 10.1016/j.ejphar.2005.10.005
The gamma-aminobutyric acidB (GABA(B)) receptor full agonists, baclofen and CGP44532, have been found to suppress different aspects of alcohol drinking behavior, including acquisition and maintenance, in selectively bred Sardinian alcohol-preferring (sP) rats. The present study was designed to assess whether this capability extends to the recently synthesized, positive allosteric modulators of the GABA(B) receptor, 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783). In the "acquisition" experiments, CGP7930 (0, 25, 50 and 100 mg/kg; i.g.) and GS39783 (0, 6.25, 12.5 and 25 mg/kg; i.g.) were administered for 5 consecutive days to alcohol-naive sP rats. In the "maintenance" experiments, (0, 50 and 100 mg/kg; i.g.) and GS39783 (0, 50 and 100 mg/kg; i.g.) were administered for 5 consecutive days to alcohol-experienced sP rats. Alcohol intake was evaluated under the standard, homecage 2-bottle "alcohol (10%, v/v) vs water" regimen with unlimited access for 24 h/day. Both CGP7930 and GS39783 dose-dependently suppressed the acquisition of alcohol drinking behavior. In the "maintenance" experiments, CGP7930 and GS39783 reduced daily alcohol intake by 30-40% only at the highest dose when compared to vehicle-treated rats; this effect tended to vanish on continuing treatment. The results of the present study suggest that positive allosteric modulation of the GABA(B) receptor produced an effect on alcohol drinking behavior similar to that produced by GABA(B) receptor full agonists. These data also suggest that positive allosteric modulation of the GABA(B) receptor may constitute a potential strategy for developing new drugs for treating alcohol dependence.
Available from: Anna Sadakierska-Chudy
- "l consumption . This drug entirely abolished alcohol intake during the initial ( 15 min ) period of the study , which may implicate its effects on eliminating alcohol " front - loading " and overall intake during the whole session . Interestingly , repeated treatment with CGP7930 , GS39783 or rac - BHFF resulted in a reduced daily alcohol intake ( Orrù et al . , 2005 ; Loi et al . , 2013 ) , with the most efficacious action observed for rac - BHFF ( up to a 7 - day treatment period ) , suggesting no tolerance to the inhibitory ef - fects . Most recent report by Hwa et al . ( 2014 ) showed that ADX 71441 markedly and specifically reduce alcohol consumption in mouse models of " binge " - like drinking"
[Show abstract] [Hide abstract]
ABSTRACT: γ-Aminobutyric acid B (GABAB) receptors and their ligands are postulated as potential therapeutic targets for the treatment of several brain disorders, including drug dependence. Over the past fifteen years positive allosteric modulators (PAMs) have emerged that enhance the effects of GABA at GABAB receptors and which may have therapeutic effects similar to those of agonists but with superior side-effect profiles. This review summarizes current preclinical evidence supporting a role of GABAB receptor PAMs in drug addiction in several paradigms with relevance to reward processes and drug abuse liability. Extensive behavioral research in recent years has indicated that PAMs of GABAB receptors may have a therapeutic efficacy in cocaine, nicotine, amphetamine and alcohol dependence. The magnitude of the effects observed are similar to that of the clinically approved drug baclofen, an agonist at GABAB receptors. Moreover, given that anxiolytic effects are also reported with such ligands they may also benefit in mitigating the withdrawal from drugs of abuse. In summary, a wealth of data now supports the benefits of GABAB receptor PAMs and clinical validation is now warranted.
Neuropharmacology 06/2014; 88. DOI:10.1016/j.neuropharm.2014.06.016 · 5.11 Impact Factor
Available from: Roberta Agabio
- "Virtually all studies conducted to date demonstrate that the “anti-alcohol” effects of baclofen and other GABAB receptor agonists may be reproduced by treatment with the currently available, in vivo effective GABAB PAMs (namely, CGP7930, GS39783, BHF177, rac-BHFF, and ADX71441). Specifically, repeated (once daily for 5–7 consecutive days) treatment with CGP7930 (25–100 mg/kg, i.g.), GS39783 (6.25–100 mg/kg, i.g.), and rac-BHFF (50–200 mg/kg, i.g.) has been reported to reduce daily alcohol intake in sP rats exposed to the 2-bottle “alcohol vs water” choice regimen (Orrù et al., 2005; Loi et al., 2013); daily water intake was compensatorily increased, leading to exclude that reduction in alcohol drinking was secondary to sedation. More recently, acute treatment with ADX71441 (3–30 mg/kg, i.g.) reduced alcohol intake in C57BL/6J mice exposed to (a) a model of excessive alcohol drinking based on the intermittent access, once every other day, to 20% (v/v) alcohol [this procedure is known to powerfully generate daily intakes of alcohol larger than 20 g/kg in C57BL/6J mice (Hwa et al., 2011)], and (b) the DID model of binge-like drinking (Hwa et al., 2014). "
[Show abstract] [Hide abstract]
ABSTRACT: The present paper summarizes the preclinical and clinical studies conducted to define the "anti-alcohol" pharmacological profile of the prototypic GABAB receptor agonist, baclofen, and its therapeutic potential for treatment of alcohol use disorder (AUD). Numerous studies have reported baclofen-induced suppression of alcohol drinking (including relapse- and binge-like drinking) and alcohol reinforcing, motivational, stimulating, and rewarding properties in rodents and monkeys. The majority of clinical surveys conducted to date-including case reports, retrospective chart reviews, and randomized placebo-controlled studies-suggest the ability of baclofen to suppress alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in alcohol-dependent patients. The recent identification of a positive allosteric modulatory binding site, together with the synthesis of in vivo effective ligands, represents a novel, and likely more favorable, option for pharmacological manipulations of the GABAB receptor. Accordingly, data collected to date suggest that positive allosteric modulators of the GABAB receptor reproduce several "anti-alcohol" effects of baclofen and display a higher therapeutic index (with larger separation-in terms of doses-between "anti-alcohol" effects and sedation).
Frontiers in Neuroscience 06/2014; 8(8):140. DOI:10.3389/fnins.2014.00140 · 3.66 Impact Factor
Available from: Lara S Hwa
- "It has been proposed that this feature enables PAMs to produce less adverse effects and leads to less tolerance than direct agonists (May and Christopoulos 2003; Langmead and Christopolous 2006; Perdona et al. 2011; Urwyler 2011). Preclinical findings support this proposal, as ethanol-suppressing effects of GABA B R PAMs are associated with compensatory increases in water drinking (Orrù et al. 2005; Loi et al. 2013), while having no effect on self-administration of sucrose (Maccioni et al. 2007, 2008b, 2009, 2010). Microinfusion of GS39783 into the ventral tegmental area reduces ethanol-seeking behavior in rats without concurrent changes in spontaneous locomotor activity (Leite-Morris et al. 2009). "
[Show abstract] [Hide abstract]
ABSTRACT: A promising pharmacotherapy for alcohol use disorders has been positive allosteric modulators (PAMs) of the γ-aminobutyric acid receptor B (GABAB R) since GABAB R PAMs reduce ethanol drinking and self-administration in rodents.
The current studies investigated a novel, selective GABAB R PAM, ADX71441, in comparison to naltrexone in a protocol of ethanol binge-like drinking, drinking-in-the-dark (DID), and in a model of long-term, excessive drinking, intermittent access to ethanol (IA).
Male C57BL/6 J mice were given doses of ADX71441 (3, 10, 30 mg/kg, p.o.) before the fourth test day of repeated DID access to 20 % ethanol. Another group of mice had a history of 4 weeks of IA before ADX71441 (3, 10, 17 mg/kg, p.o.) treatment. The opioid antagonist, naltrexone (0.1, 1, 10 mg/kg, i.p.), was administered to different groups of mice in both protocols as a positive control.
In both DID and IA protocols, ADX71441 showed a selective and potent reduction of ethanol drinking, but not water drinking, while naltrexone had a more modest and transient effect on reducing ethanol drinking. The long-lasting effect of ADX71441 agrees with its plasma pharmacokinetics in showing peak concentrations at 2 h followed by a slow decay lasting well beyond 8 h.
These findings support previous studies demonstrating that GABAB R PAMs decrease voluntary ethanol intake without altering water intake. ADX71441 may be a worthwhile candidate for developing a treatment of alcoholism, yet its site of action in the brain and long-term pharmacological effects require further exploration.
Psychopharmacology 08/2013; 231(2). DOI:10.1007/s00213-013-3245-z · 3.88 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.